Target intelligence / Profile preview

Ribosomal protein L17 pseudogene 29 (RPL17P29)

Target: RPL17P29
Molecular classification: Other, Pseudogene[13][14]

Overview

Ribosomal protein L17 pseudogene 29 (RPL17P29) is a non-coding genomic element classified as a processed pseudogene of the ribosomal protein L17 gene family in humans. Like most ribosomal protein pseudogenes, RPL17P29 does not produce a functional protein and is not known to play a biological role or be involved in any diseases or therapeutic processes[13][14]. Its sequence is retained in the genome as a result of gene duplication followed by mutations that prevent protein-coding function.

Other names: RPL17_18_874RPL17P29[6][11][13]

Mechanism of action

No mechanism of drug action applies as the pseudogene is not an active target.

Beyond the preview

Go deeper on Ribosomal protein L17 pseudogene 29 (RPL17P29).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L17 pseudogene 29 (RPL17P29).

Explore the full profile